SCHEMBL6982244

SCHEMBL6982244

O=C(c1ccc2c(c1)CCCN2)N1CCCCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
MAPT P10636 1/20 0.64
HPGD P15428 9/20 0.53
ALDH1A1 P00352 1/20 0.53
CRBN Q96SW2 1/20 0.50
MASP2 O00187 1/20 0.47
F2 P00734 1/20 0.47
TSHR P16473 2/20 0.47
RECQL P46063 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
ACHE P22303 1/20 0.46
GRIA3 P42263 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22226394 0.93 CRBN (0.57) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL30226900 0.93 CRBN (0.57) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL30226880 0.91 CRBN (0.58) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL6978588 0.88 KDM4E (0.59) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL30031951 0.87 MAPT (0.58) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL6976973 0.85 KDM4E (0.57) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL17346260 0.82 HPGD (0.59) HPGDALDH1A1TSHRRECQLCYP1A2
SCHEMBL6980782 0.80 KDM4E (0.60) KDM4EMAPTHPGDALDH1A1CRBN
SCHEMBL698914 0.80 KDM4E (0.53) KDM4EMAPTALDH1A1CRBNMASP2
SCHEMBL22895588 0.79 CRBN (0.58) HPGDALDH1A1CRBNTSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335043-B PGDH inhibitors and methods of making and using the same 迈欧伏特治疗公司 2025-03-28 CN disclosed
CN-117377668-A Inhalant formulations of PGDH inhibitors and methods of use thereof 迈欧伏特治疗公司 2024-01-09 CN disclosed
EP-4228650-A1 INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF Epirium Bio Inc. (US) 2023-08-23 EP disclosed
EP-4093385-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING Myoforte Therapeutics Inc. (US) 2022-11-30 EP disclosed
CN-115335043-A PGDH inhibitors and methods of making and using 迈欧伏特治疗公司 2022-11-11 CN disclosed
US-11345702-B1 PGDH inhibitors and methods of making and using MYOFORTE THERAPEUTICS, INC. (US) 2022-05-31 US disclosed
WO-2022082009-A1 INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF EPIRIUM BIO INC. (US) 2022-04-21 WO disclosed
EP-3922247-A1 15-PGDH INHIBITOR Kyorin Pharmaceutical Co., Ltd. (JP) 2021-12-15 EP disclosed
WO-2021151014-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING MYOFORTE THERAPEUTICS, INC. (US) 2021-07-29 WO disclosed
WO-2020145250-A1 15-PGDH INHIBITOR 杏林製薬株式会社 2020-07-16 WO disclosed
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345702-B1 PGDH inhibitors and methods of making and using HPGD, HPGDS, PTGS1 KDM4E 3758/4885MAPT 4693/4885HPGD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.